103 results about "Donepezil Hydrochloride" patented technology

The invention relates to a donepezil hydrochloride orally disintegrating tablet and a preparation method thereof, in particular to an orally disintegrating tablet taking donepezil hydrochloride as main medicine and a preparation method thereof. The donepezil hydrochloride orally disintegrating tablet can be used for treating Alzheimer's Association.

A medicament for prophylactic and/or therapeutic treatment of Alzheimer-type dementia, which comprises donepezil hydrochloride and valproic acid or a salt thereof in combination.

The present invention relates to an improved process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride of Formula I.

A taste-masking composition for donepezil hydrochloride is prepared from mannitol, trichlorosucrose, gelatin and xanthan gum. It can be mixed with donepezil for masking the irritative taste of donepezil, and can be used to prepare the oral disintegrating tablet.

The invention relates to a donepezil hydrochloride dispersible tablet and a preparation method thereof, and belongs to the technical field of medicines. The donepezil hydrochloride dispersible tablet comprises the following components in percentage by weight: 1-5 percent of donepezil hydrochloride, 40-90 percent of disintegrating agent, 1-15 percent of lubricant and glidant and 1-15 percent of adhesive. The preparation method comprises the following steps: screening the components; uniformly mixing the donepezil hydrochloride and the disintegrating agent; adding the adhesive to prepare a soft material; granulating, baking and straightening granulating; adding the disintegrating agent, the lubricant and the glidant, and uniformly mixing; determining tablet weight, and tabletting to obtain the oxycodone hydrochloride dispersible tablet. The medicine is mainly used for treating senile dementia, especially mild or moderate alzheimer disease in clinical application, has stable quality, is beneficial to drug dissolution and absorption, is quick in response and convenient to take, can be taken orally after being dispersed with water, and also can be sucked in the mouth or swallowed.

A process for preparing crystalline form I of donepezil hydrochloride comprises: a) condensing 5,6-dimethoxy-2-piperidin-4-yl-methyl-indan-1-one with benzyl bromide and reacting a condensation product with hydrobromic acid to form donepezil hydrobromide; and b) hydrolyzing donepezil hydrobromide, followed by reacting with aqueous hydrochloric acid.

The invention provides a memantine hydrochloride slow release-donepezil quick release compound capsule. The compound capsule is prepared by jointly filling a capsule with memantine hydrochloride slow release pellets and donepezil quick release granules; the memantine hydrochloride slow release pellets are prepared by using medicinal empty pellet cores as original cores, dissolving memantine hydrochloride serving as main drug and proper excipients to form coating liquid, spraying the coating liquid to the bottom of a fluidized bed to form a drug-containing layer and sequentially coating the fluidized bed with an isolating layer and a slow release layer from inside to outside; the donepezil quick release granules are formed by subjecting donepezil hydrochloride serving as main drug and proper excipients to wet-process granulation, and the slow release pellets and quick release granules are filled into one same capsule according to a certain proportion of the main drug.

The invention discloses a sustained release tablet containing a donepezil hydrochloride serving as an active component. The sustained release tablet provided by the invention comprises the donepezil hydrochloride serving as an active component, a sustained-release material and other auxiliary materials, wherein the weight ratio of the donepezil hydrochloride serving as an active component to the sustained-release material is 1:(0.2-20), preferably 1:(0.5-10) and further preferably 1:(0.7-8). The sustained release tablet containing donepezil hydrochloride prepared by the invention is released steadily, which is favorable for the reduction of the fluctuation of the in-vivo medicament, thus the side effect is reduced, and the sustained release tablet is more suitable for treating patients suffering from Alzheimer-type dementia.

The invention provides a method for preparing donepezil hydrochloride, which comprises the steps as follows: (1) 5,6-dimethoxy-2-(4-pyridyl)methylene-1-idenone (II) is taken as a starting material, and is processed through catalytic hydrogenation under the action of platinum dioxides, so as to generate compounds that are 5,6-dimethoxy-2-(4-piperidyl)methylene-2,3-dihydro-1-idenone (III); (2) the obtained compounds (III) and benzaldehyde are processed through condensation, so as to generate 1-benzyl-4-[(5,6-dimethoxy-1-idenone)-2-methylene]piperidine (IV); and (3) the obtained compounds (IV) and hydrogen chloride are processed through salifying, so as to generate 1-benzyl-4-[(5,6-dimethoxy-1-idenone)-2-methylene]piperidine hydrochloride that is donepezil hydrochloride (I). In the method for preparing donepezil hydrochloride, 5,6-dimethoxy-2-(4-pyridyl)methylene-1-idenone is taken as the starting material, and three-step reaction comprising catalytic hydrogenation, condensation and salifying are adopted to prepare donepezil hydrochloride. The method is simple and efficient to operate, has the advantages of mild reaction conditions, high safety and higher yield coefficient, is easy to control, and is suitable for industrialized production.

Donepezil hydrochloride guttate pills contains Donepezil hydrochloride 6-16 wt%, water soluble supplementary material polyglycol-4000 0-94 wt% and polyethenoxy searate 0-94 wt%. The present invention is easy in separating dosage and has high biological utilization, stable quality and easy-to-control production condition.

The invention discloses a donepezil hydrochloride orally disintegrating tablet. The main medicine of the donepezil hydrochloride orally disintegrating tablet is donepezil hydrochloride; and the auxiliary medicines of the donepezil hydrochloride orally disintegrating tablet comprise mannitol, microcrystalline cellulose, hyprolose, crospovidone, sodium bicarbonate, citric acid, soluble saccharin, carboxymethyl starch sodium, magnesium stearate and essence. The invention can preferably treat the low-degree or moderate-degree alzheimer type dementia, can preferably improve the cognitive dysfunction, the mental and behavioral abnormalities and the daily self-care ability of the patient who suffers from the alzheimer type dementia (AD), can alleviate the dementia degree, is convenient to take, can fast disintegrate, and is convenient for the old or the patient who has medication obstacles or is hard to take water.

The present invention discloses a novel, stable polymorph of 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and it's polymorph Form (VI).

The invention discloses a refining method of a key intermediate of 2-(1-benzyl-piperidine-4-methyl alkenyl)-5, 6 dimethoxy-indanone of Donepezil, namely, a compound (I), and the method is to obtain the high purity compound (I) by agitating a crude product of the compound (I) in the presence of inorganic base in a benzenoid aromatic hydrocarbon-containing organic solvent of C6 to C12 at a certain temperature. The method has advantages of simple operation, short reaction time, single solvent and low cost, and is suitable for the industrialized production.

The invention provides an orally disintegrating tablet containing donepezil hydrochloride and a preparation method thereof. The orally disintegrating tablet comprises donepezil hydrochloride, mannitol, microcrystalline cellulose, and a disintegrating agent. By controlling the using amounts of mannitol and microcrystalline cellulose, the orally disintegrating tablet having the advantages of rapid disintegration, low friability, good taste, and simple technology is obtained.

The present invention provides a simple method of producing polymorphic crystal (III), which has high safety to environment and the bodies of operators; is gentle to environment; and can produce at low costs; and has a high refining effect. It is a method of producing polymorphic crystal (III) of donepezil hydrochloride (chemical name: 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine.monohydrochloride) represented by the following structural formula (formula (I)), which comprises dissolving donepezil (chemical name: 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) in ethanol; and adding hydrochloric acid or hydrogen chloride thereto, followed by stirring.

The invention provides a preparation method of three donepezil hydrochloride impurities, which comprises the following steps: 1) impurity 1: by using 5,6-dimethoxy-2-(4-piperidylmethylene)-1-indeneone (SM) as an initial raw material, generating 4-(5,6-dimethoxy-1-indene-2-methylene)piperidine (I) under the action of sodium borohydride, carrying out Pd/C reduction to generate 4-(2,3-dihydro-5,6-dimethoxy-1-indene-2-methylene)piperidine (II), and finally, carrying out formylation to generate 4-(2,3-dihydro-5,6-dimethoxy-1-indene-2-methylene)piperidine-1-formaldehyde (1); 2) impurity 2: by using the 4-(5,6-dimethoxy-1-indene-2-methylene)piperidine (I) as the raw material, carrying out formylation to generate 4-(5,6-dimethoxy-1-indene-2-methylene)piperidine-1-formaldehyde (2); and 3) impurity 3: by using the 5,6-dimethoxy-2-(4-piperidylmethylene)-1-indeneone (SM) as the initial raw material, carrying out formylation to generate 4-(2,3-dihydro-5,6-dimethoxy-1-indeneone-2-methylene)piperidine-1-formaldehyde (3). The preparation of the donepezil hydrochloride impurities has important quality monitoring meanings for industrial production of the donepezil hydrochloride active pharmaceutical ingredient.

The invention discloses a catalyst for hydrogenation reaction of a donepezil hydrochloride key intermediate and application thereof. The key intermediate is 2-(1-benzyl-4-piperidine methylene)-5,6-dimethoxy-1-indenone. The catalyst takes Al2O3 as a carrier and comprises composite active components selected from one or several simple substances or the simple substances and oxides of Pd, Cu, Co, Ni, Zn, Fe and Cr, wherein the mass content of each active component is 1-15 percent of the total mass of the catalyst and the total content of the active components is 5-30 percent of the total mass of the catalyst. The catalyst is prepared by utilizing a conventional catalyst preparation method and has the characteristics of low cost, stable activity and cycle use. The hydrogenation reaction by applying the catalyst has the characteristics of easy control of operation conditions, good catalyst performance and high product yield.

The present invention adopts memantine hydrochloride and donepezil hydrochloride as the active ingredients of the medicine, and co-wraps the memantine hydrochloride and donepezil hydrochloride on the pellets, and controls the slow release of memantine hydrochloride and the rapid release of donepezil hydrochloride through multi-layer coating, It is finally filled in capsules, which also avoids the problem of uneven filling that may exist in capsules mixed with pellets and granules, and is easier to realize industrial production. There is no lactose and other excipients that can undergo Maillard reactions with memantine hydrochloride, ensuring formulation stability.

The invention relates to new compounds of formula (III):

wherein R is a C₁-C₄ linear or branched alkyl group.

The invention also relates to new compounds of formula (IV)

wherein M is a metal.

The invention also relates to methods of making compounds of formulas (III) and (IV) and to methods of making donepezil and pharmaceutically acceptable salts thereof, such as donepezil hydrochloride, using the compounds.

The present invention provides an inhalation-type pharmaceutical composition for Alzheimer's disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising rivastigmine hydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide, memantine hydrochloride, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.